JP2014513126A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014513126A5 JP2014513126A5 JP2014509386A JP2014509386A JP2014513126A5 JP 2014513126 A5 JP2014513126 A5 JP 2014513126A5 JP 2014509386 A JP2014509386 A JP 2014509386A JP 2014509386 A JP2014509386 A JP 2014509386A JP 2014513126 A5 JP2014513126 A5 JP 2014513126A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cell
- composition according
- activated
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 7
- 210000000447 Th1 cell Anatomy 0.000 claims 5
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 108010029697 CD40 Ligand Proteins 0.000 claims 2
- 102100032937 CD40 ligand Human genes 0.000 claims 2
- 108010039471 Fas Ligand Protein Proteins 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 230000000961 alloantigen Effects 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 230000000050 nutritive effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161482009P | 2011-05-03 | 2011-05-03 | |
| US61/482,009 | 2011-05-03 | ||
| US201161528484P | 2011-08-29 | 2011-08-29 | |
| US61/528,484 | 2011-08-29 | ||
| US201161564551P | 2011-11-29 | 2011-11-29 | |
| US61/564,551 | 2011-11-29 | ||
| US201261582881P | 2012-01-04 | 2012-01-04 | |
| US61/582,881 | 2012-01-04 | ||
| PCT/US2012/036123 WO2012151279A2 (en) | 2011-05-03 | 2012-05-02 | Induction of il-12 using immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017079200A Division JP6615148B2 (ja) | 2011-05-03 | 2017-04-12 | 免疫療法を用いたｉｌ−１２の誘導 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014513126A JP2014513126A (ja) | 2014-05-29 |
| JP2014513126A5 true JP2014513126A5 (enExample) | 2015-06-25 |
| JP6393186B2 JP6393186B2 (ja) | 2018-09-19 |
Family
ID=47108207
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014509386A Active JP6393186B2 (ja) | 2011-05-03 | 2012-05-02 | 免疫療法を用いたｉｌ−１２の誘導 |
| JP2017079200A Active JP6615148B2 (ja) | 2011-05-03 | 2017-04-12 | 免疫療法を用いたｉｌ−１２の誘導 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017079200A Active JP6615148B2 (ja) | 2011-05-03 | 2017-04-12 | 免疫療法を用いたｉｌ−１２の誘導 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9233156B2 (enExample) |
| EP (1) | EP2704732B1 (enExample) |
| JP (2) | JP6393186B2 (enExample) |
| KR (1) | KR102121492B1 (enExample) |
| CN (2) | CN103687602A (enExample) |
| AU (3) | AU2012250807A1 (enExample) |
| BR (1) | BR112013028285A2 (enExample) |
| CA (1) | CA2838046C (enExample) |
| IL (1) | IL229177B (enExample) |
| PH (1) | PH12013502252B1 (enExample) |
| SG (2) | SG194753A1 (enExample) |
| WO (1) | WO2012151279A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG194753A1 (en) | 2011-05-03 | 2013-12-30 | Immunovative Therapies Ltd | Induction of il-12 using immunotherapy |
| FI3077041T3 (fi) | 2013-12-05 | 2024-10-16 | Rfemb Holdings Llc | Syövän immunoterapia radiotaajuisella sähköisellä solukalvon hajotuksella (rf-emb) |
| JP6202339B2 (ja) * | 2013-12-19 | 2017-09-27 | 国立研究開発法人国立精神・神経医療研究センター | ＧＭ−ＣＳＦ産生Ｔ細胞制御剤、及びＴｈ１／Ｔｈ２免疫バランス調節剤 |
| CA2975123A1 (en) | 2015-01-30 | 2016-08-04 | Rfemb Holdings, Llc | Radio frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue |
| CA3011460A1 (en) | 2016-01-15 | 2017-07-20 | Rfemb Holdings, Llc | Immunologic treatment of cancer |
| CN111163786A (zh) * | 2017-07-14 | 2020-05-15 | 徐民桢 | 用于诱导m1优势免疫应答的方法和药物组合物 |
| US12605349B2 (en) | 2024-09-05 | 2026-04-21 | Orbus Therapeutics, Inc. | Methods of treating grade 3 astrocytoma |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2439003A1 (fr) | 1978-10-20 | 1980-05-16 | Anvar | Nouvelles pieces d'osteosynthese, leur preparation et leur application |
| US5766920A (en) | 1982-08-11 | 1998-06-16 | Cellcor, Inc. | Ex vivo activation of immune cells |
| WO1988000970A2 (en) | 1986-08-08 | 1988-02-11 | Regents Of The University Of Minnesota | Method of culturing leukocytes |
| AU2635088A (en) | 1987-12-04 | 1989-06-08 | Du Pont Merck Pharmaceutical Company, The | Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5126132A (en) | 1989-08-21 | 1992-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor infiltrating lymphocytes as a treatment modality for human cancer |
| US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
| JPH0455577A (ja) * | 1990-06-22 | 1992-02-24 | Mitsubishi Electric Corp | 構造物の制振装置 |
| AU5729294A (en) | 1992-11-25 | 1994-06-22 | Tanox Biosystems, Inc. | Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules |
| EP0726941B1 (en) | 1993-08-06 | 2002-04-03 | Epimmune Inc. | Methods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl |
| IL107483A0 (en) | 1993-11-03 | 1994-02-27 | Yeda Res & Dev | Bone marrow transplantation |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| WO1996027392A1 (en) | 1995-03-08 | 1996-09-12 | The Scripps Research Institute | Antigen presenting system and methods for activation of t-cells |
| DE19545257A1 (de) | 1995-11-24 | 1997-06-19 | Schering Ag | Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln |
| JPH09255577A (ja) * | 1996-03-27 | 1997-09-30 | Dainippon Ink & Chem Inc | インターリュウキン−１２誘導剤 |
| IL126843A (en) | 1996-05-23 | 2007-06-17 | Scripps Research Inst | Mhc class ii antigen-presenting systems and methods for activating cd4+t cells in vitro |
| WO1998024483A2 (en) | 1996-12-03 | 1998-06-11 | Osteobiologics, Inc. | Biodegradable polymeric film |
| CA2278847A1 (en) | 1997-01-31 | 1998-08-06 | Hemosol Inc. | Method for the production of selected lymphocytes |
| EP1014897B1 (en) | 1997-05-30 | 2008-10-29 | Osteobiologics, Inc. | Fiber-reinforced, porous, biodegradable implant device |
| CA2309206A1 (en) | 1997-11-10 | 1999-05-20 | Arch Development Corporation | Methods for treatment of tumors and tumor cells using ex vivo activated t cells |
| AU4518400A (en) | 1999-07-12 | 2001-01-18 | Isotis B.V. | Sutures |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US20030119185A1 (en) | 2000-02-24 | 2003-06-26 | Xcyte Therapies, Inc. | Activation and expansion of cells |
| HK1052372A1 (zh) | 2000-02-24 | 2003-09-11 | Xcyte Therapies, Inc. | 细胞的同步刺激和富集 |
| WO2001062092A1 (en) * | 2000-02-25 | 2001-08-30 | Thomas Jefferson University | Formulations and methods for using the same to elicit an immune response |
| US20020127208A1 (en) | 2000-08-31 | 2002-09-12 | Waller Edmund K. | Method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease |
| US6626950B2 (en) | 2001-06-28 | 2003-09-30 | Ethicon, Inc. | Composite scaffold with post anchor for the repair and regeneration of tissue |
| WO2003038062A2 (en) | 2001-10-31 | 2003-05-08 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Generation of use of tc1 and tc2 cells |
| US20030134415A1 (en) * | 2001-09-19 | 2003-07-17 | Gruenberg Micheal L. | Th1 cell adoptive immunotherapy |
| WO2003053216A2 (en) | 2001-12-06 | 2003-07-03 | University Of Washington | Biodegradable, porous structures useful for growing living tissue, and methods of manufacture |
| US20030175272A1 (en) | 2002-03-07 | 2003-09-18 | Medcell Biologics, Inc. | Re-activated T-cells for adoptive immunotherapy |
| DE10230223A1 (de) | 2002-07-04 | 2004-01-22 | Tegenero Ag | Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern |
| CN1399054A (zh) * | 2002-09-03 | 2003-02-26 | 宋有财 | 旋转式的泊车装置 |
| US7402431B2 (en) | 2004-03-01 | 2008-07-22 | Immunovative Therapies, Ltd. | T-cell therapy formulation |
| US20110142887A1 (en) * | 2009-12-15 | 2011-06-16 | Immunovative Therapies Ltd. | Methods and compositions for liquidation of tumors |
| US7435592B2 (en) * | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
| US7371228B2 (en) | 2003-09-19 | 2008-05-13 | Medtronic Vascular, Inc. | Delivery of therapeutics to treat aneurysms |
| JP2007525225A (ja) | 2004-02-26 | 2007-09-06 | イミュノバティブ セラピーズ， リミテッド | 細胞治療のためのｔ細胞を調製するための方法 |
| US7592431B2 (en) | 2004-02-26 | 2009-09-22 | Immunovative Therapies, Ltd. | Biodegradable T-cell Activation device |
| US7446099B2 (en) | 2004-02-27 | 2008-11-04 | Nitto Denko Corporation | Compositions and methods for biodegradable polymer-peptide mediated transfection |
| EP1749090B1 (en) | 2004-03-01 | 2017-05-17 | Immunovative Therapies, Ltd. | Cell therapy formulation method and composition |
| WO2005089127A2 (en) | 2004-03-05 | 2005-09-29 | The Trustees Of Columbia University In The City Of New York | Polymer-ceramic-hydrogel composite scaffold for osteochondral repair |
| US8865224B2 (en) * | 2004-10-14 | 2014-10-21 | Immunovative Therapies Ltd. | Allogeneic cellular immunotherapy for opportunistic infection |
| CA2649290C (en) * | 2006-04-13 | 2017-04-04 | Immunovative Therapies, Ltd. | Allogeneic cell therapy for treatment of opportunistic infection |
| US20080112963A1 (en) * | 2006-11-13 | 2008-05-15 | Immunovative Therapies, Ltd. | Ablative immunotherapy |
| US7972594B2 (en) * | 2006-11-13 | 2011-07-05 | Immunovative Therapies Ltd. | Ablative immunotherapy |
| EP2025746A1 (en) * | 2007-08-16 | 2009-02-18 | Cell Med Research GMBH | Dendritic cells |
| US20120128656A1 (en) * | 2008-05-02 | 2012-05-24 | Immunovative Therapies, Ltd. | Vaccine compositions and methods |
| SG194753A1 (en) | 2011-05-03 | 2013-12-30 | Immunovative Therapies Ltd | Induction of il-12 using immunotherapy |
-
2012
- 2012-05-02 SG SG2013081302A patent/SG194753A1/en unknown
- 2012-05-02 CN CN201280021818.0A patent/CN103687602A/zh active Pending
- 2012-05-02 KR KR1020137032017A patent/KR102121492B1/ko active Active
- 2012-05-02 SG SG10201901391RA patent/SG10201901391RA/en unknown
- 2012-05-02 CA CA2838046A patent/CA2838046C/en active Active
- 2012-05-02 BR BR112013028285A patent/BR112013028285A2/pt not_active Application Discontinuation
- 2012-05-02 CN CN201910193492.3A patent/CN109876138A/zh active Pending
- 2012-05-02 JP JP2014509386A patent/JP6393186B2/ja active Active
- 2012-05-02 WO PCT/US2012/036123 patent/WO2012151279A2/en not_active Ceased
- 2012-05-02 PH PH1/2013/502252A patent/PH12013502252B1/en unknown
- 2012-05-02 AU AU2012250807A patent/AU2012250807A1/en not_active Abandoned
- 2012-05-02 US US13/581,745 patent/US9233156B2/en active Active
- 2012-05-02 EP EP12779711.6A patent/EP2704732B1/en active Active
-
2013
- 2013-10-31 IL IL229177A patent/IL229177B/en active IP Right Grant
-
2015
- 2015-12-08 US US14/962,728 patent/US11045541B2/en not_active Expired - Fee Related
-
2017
- 2017-04-12 JP JP2017079200A patent/JP6615148B2/ja active Active
- 2017-06-15 AU AU2017204058A patent/AU2017204058A1/en not_active Abandoned
-
2019
- 2019-07-01 AU AU2019204699A patent/AU2019204699A1/en not_active Abandoned
-
2021
- 2021-05-20 US US17/326,009 patent/US11883490B2/en active Active
-
2024
- 2024-01-17 US US18/415,111 patent/US20240148865A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11331385B2 (en) | Methods of preparing anti-human papillomavirus antigen T cells | |
| Sakuishi et al. | TIM3+ FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer | |
| Ye et al. | The significance of tumor necrosis factor receptor type II in CD8+ regulatory T cells and CD8+ effector T cells | |
| Uhlin et al. | Adjunct immunotherapies for tuberculosis | |
| JP2014087372A5 (enExample) | ||
| Ben Khelil et al. | Harnessing antitumor CD4+ T cells for cancer immunotherapy | |
| US20230310562A1 (en) | Antigen presenting scaffolds for immune-cell manipulation | |
| Hailemichael et al. | Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion | |
| JP2012521215A5 (enExample) | ||
| MY180750A (en) | Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy | |
| Nielsen et al. | Impaired NK cell responses to pertussis and H1N1 influenza vaccine antigens in human cytomegalovirus-infected individuals | |
| JP2018516586A5 (enExample) | ||
| JP2017512484A5 (enExample) | ||
| CA2642532A1 (en) | Methods for improving immune function and methods for prevention or treatment of disease in a mammalian subject | |
| JP2011006491A5 (enExample) | ||
| Hansen et al. | Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy | |
| AR057582A1 (es) | Agentes para suprimir la induccion de linfocitos t citotoxicos | |
| JP2018527932A5 (enExample) | ||
| Roberts et al. | TNF blockade maintains an IL-10+ phenotype in human effector CD4+ and CD8+ T cells | |
| JP6525946B2 (ja) | Ｔｈ１特性と細胞溶解性を発現する細胞 | |
| Wittlich et al. | Liver sinusoidal endothelial cell cross-priming is supported by CD4 T cell-derived IL-2 | |
| Li et al. | Conditions for the generation of cytotoxic CD4+ Th cells that enhance CD8+ CTL‐mediated tumor regression | |
| JP2013523886A5 (enExample) | ||
| Caserta et al. | IL‐7 is superior to IL‐2 for ex vivo expansion of tumour‐specific CD4+ T cells | |
| Suck et al. | Emerging natural killer cell immunotherapies: large-scale ex vivo production of highly potent anticancer effectors |